ClinicalTrials.gg
Active, not recruitingNCT05100862MAHOGANYUpdated Oct 15, 2026

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

A Phase 3 interventional study of Zanubrutinib and Rituximab in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by BeOne Medicines. Active, not recruiting at 264 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by BeOne Medicines · Phase 3, Interventional, and Treatment

Updated Oct 15, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
799
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing zanubrutinib in Lymphoma, Follicular — 9 open to participants now, 11 under way, 1 of them phase 3. zanubrutinib · Lymphoma, Follicular.

Enrollment
Largest of 13
799 · median 43
Started
2022
the only one that year
Phase 3
Only one
of the 13
Primary completion
2028-07
later than 6 of 10 live
Registered
3rd of 13
by date
Lead sponsor
1 of 13
BeOne Medicines

Among the 13 studies testing zanubrutinib in Lymphoma, Follicular, this one has the largest enrollment, is the only one that started in 2022, is the only one in phase 3, reaches primary completion later than 6 of the 10 other live ones, and was the 3rd registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

9 of the 13 studies testing zanubrutinib in Lymphoma, Follicular are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing zanubrutinib in Lymphoma, Follicular, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma

Keywords

  • Zanubrutinib
  • BGB-3111
  • Rituximab
  • Lenalidomide
  • Obinutuzumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed grade 1-3a FL or MZL
  • Previously treated with ≥ 1 including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
  • Need for systemic therapy for FL or MZL
  • by computed tomography or magnetic resonance imaging
  • Adequate bone marrow, liver and renal function

Key Exclusion Criteria:

  • Transformation to aggressive lymphoma
  • Requiring ongoing need for treatment
  • cardiovascular disease
  • Prior within the past 2 years
  • Active fungal, bacterial, and/or viral infection that requires systemic therapy
  • Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (\< 24 months)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
799 participants (actual)

Study arms

  • Experimental
    Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab

    Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

    Drug: Zanubrutinib · Drug: Obinutuzumab

  • Active comparator
    Follicular Lymphoma Arm B: Lenalidomide plus Rituximab

    Participants will receive lenalidomide and rituximab.

    Drug: Rituximab · Drug: Lenalidomide

  • Experimental
    Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab

    Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

    Drug: Zanubrutinib · Drug: Rituximab

  • Active comparator
    Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab

    Participants will receive lenalidomide and rituximab.

    Drug: Rituximab · Drug: Lenalidomide

Interventions

  • Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.

    Also known as: BGB-3111, Brukinsa

  • Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.

    Also known as: Rituxan, MabThera, Ruxience, Truxima

  • Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.

    Also known as: Revlimid

  • Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)

    Time frame: Approximately 78 months

Secondary outcomes

  1. Progression-free Survival As Determined By Investigator Assessment

    Time frame: Approximately 87 months

  2. Duration Of Response As Determined By BIRC And By Investigator Assessment

    Time frame: Approximately 87 months

  3. Overall Response Rate As Determined By BIRC And By Investigator Assessment

    Time frame: Approximately 87 months

  4. Complete Response Rate As Determined By BIRC And By Investigator Assessment

    Time frame: Approximately 87 months

  5. Time To Response As Determined By BIRC And By Investigator Assessment

    Time frame: Approximately 87 months

  6. Time to Next Ant-Lymphoma Treatment

    Time frame: Approximately 87 months

  7. Overall Survival

    Time frame: Approximately 87 months

  8. Health-related Quality Of Life (HRQoL) Using EORTC QLQ-C30)

    HRQ0L assessed by The European Organization For Research On Treatment Of Cancer Quality Of Life Questionnaire-core 30 (EORTC QLQ-C30) consists of 30 questions that are associated with 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and 6 single symptom items ( dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The scores range from 0 to 100 and higher score indicates better quality of life.

    Time frame: Approximately 87 months

  9. HRQoL Using European Quality of Life 5 Dimension 5 Level Questionnaire [EQ 5D 5L)

    The EQ-5D-5L is comprised of a descriptive module and a visual analogue scale. The EQ-5D-5L descriptive module comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogue scale records the respondent's self-rated health on a 0 to 100 scale, with 100 labeled "the best health you can imagine" and 0 labeled "the worst health you can imagine. Higher scores indicate better quality of life.

    Time frame: Approximately 87 months

  10. HRQoL Using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 [FLymSI 18)

    The FLymSI-18 is comprised of 18 questions which cover 4 sub-scales: physical symptoms, emotional symptoms, side effects, and functional well-being. Scores are based on the 5-level Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score. Higher score indicates better quality of life.

    Time frame: Approximately 87 months

  11. Number of Participants Experiencing Adverse Events (AEs)

    Time frame: From first dose to 28 days after the last dose of zanubrutinib or lenalidomide, 90 days after the last dose of obinutuzumab or rituximab, or until the date of confirmed disease progression, whichever comes later (Approximately 87 months)

07

Study locations

264 sites

Showing the first 100 of 264 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2028, 76 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's planned 76 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 29, 2021
StartActual
Mar 10, 2022
Primary completionEst.
Jul 2028
CompletionEst.
Jun 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (2 United States, 1 Brazil)
  • Cancer Care Specialists of Illinois · OFallon, United States
  • Hcfmusp Pesquisa Clinica Do Servico de Hematologia E Terapia Celular · São Paulo, Brazil
  • Texas Oncology Baylor Charles A Sammons Cancer Center · Dallas, United States
Show 3 removed
  • Cancer Care Specialists of Illinois · Decatur, United States
  • Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular · São Paulo, Brazil
  • Texas Oncology Baylorcharles A Sammons Cancer Center · Dallas, United States
across 2 updates, Sep 28, 2026 – Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    1 site added, 1 site removed
    Show site
    • Texas Oncology Baylor Charles A Sammons Cancer Center · Dallas, United States
    Show 1 removed
    • Texas Oncology Baylorcharles A Sammons Cancer Center · Dallas, United States
  2. Sep 28, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Brazil)
    • Cancer Care Specialists of Illinois · OFallon, United States
    • Hcfmusp Pesquisa Clinica Do Servico de Hematologia E Terapia Celular · São Paulo, Brazil
    Show 2 removed
    • Cancer Care Specialists of Illinois · Decatur, United States
    • Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular · São Paulo, Brazil

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05100862
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Oct 29, 2021
Start date
Mar 10, 2022
Primary completion
Jul 2028 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Study Director
study director · BeOne Medicines
Study Director
principal investigator · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Rituximab

Start the discussion